Sascha D.
- Country
- Germany
- Department
- Klinik für Hämatologie, Onkologie und Klinische Immunologie
Research Overview
- Phase II Study of Glofitamab-Based Induction Followed by CAR‑T Cell Therapy in High‑Risk Relapsed/Refractory Large B‑Cell Lymphoma
- Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B)
- Phase 2 Multicenter Study of Rituximab, Polatuzumab Vedotin, and Glofitamab in Untreated Aggressive B-cell Lymphoma Patients Aged >60 Ineligible for R-CHOP
Data & Insights
Has run more than one trial at 37 of 114 partner sites.
Specializations
Hematologic malignancies
Clinical research activity includes a broad focus on acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, and aggressive B-cell lymphoma entities, with additional involvement in mantle cell lymphoma, follicular lymphoma, and multiple myeloma.
- Acute myeloid leukemia
- Acute lymphoblastic leukemia
- Myelodysplastic syndromes
- Diffuse large B-cell lymphoma
- Multiple myeloma
Research interests also extend to allogeneic stem cell transplantation, graft-versus-host disease, and post-transplant infection management in high-risk blood cancers.
Breast and gynecologic oncology
The investigator is active in breast cancer research across early, locally advanced, and metastatic settings, including HER2-positive, HER2-negative, and triple-negative breast cancer, as well as ovarian cancer, endometrial cancer, and vulvar cancer.
- HER2-positive breast cancer
- Hormone receptor-positive breast cancer
- Triple-negative breast cancer
- Ovarian epithelial cancer
- Endometrial cancer
Interest also covers neoadjuvant and adjuvant treatment strategies aimed at improving disease control in solid tumors of the female reproductive tract and breast.
Autoimmune and inflammatory disease
Clinical trial involvement spans systemic lupus erythematosus, lupus nephritis, systemic sclerosis, rheumatoid arthritis, idiopathic inflammatory myopathy, and myasthenia gravis, alongside hidradenitis suppurativa and psoriasis.
- Systemic lupus erythematosus
- Systemic sclerosis
- Rheumatoid arthritis
- Myasthenia gravis
- Hidradenitis suppurativa
Additional therapeutic interest includes autoimmune blistering disease, vasculitis, and inflammatory lung involvement linked to systemic autoimmune disorders.
Neurology and neuroimmunology
Research activities include multiple sclerosis in relapsing and progressive forms, Parkinson’s disease, progressive supranuclear palsy, autoimmune encephalitis, and myelin oligodendrocyte glycoprotein antibody-associated disease.
- Multiple sclerosis
- Parkinson’s disease
- Progressive supranuclear palsy
- Autoimmune encephalitis
- Myelin oligodendrocyte glycoprotein antibody-associated disease
The portfolio also includes neurodegenerative disease and inflammatory central nervous system disorders, reflecting interest in complex neurological therapeutics.
Solid tumors and transplant-related innovation
The investigator also works across prostate cancer, urothelial cancer, colorectal cancer, hepatocellular carcinoma, cholangiocarcinoma, and head and neck squamous cell carcinoma, with activity in targeted therapy and immuno-oncology.
- Prostate cancer
- Urothelial cancer
- Colorectal cancer
- Hepatocellular carcinoma
- Cholangiocarcinoma
Additional involvement includes gene-modified T-cell therapy, hematopoietic stem cell transplantation, and treatment of chronic viral hepatitis and HIV infection.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.